Acquisition Of Prostiva Radio Frequency Therapy (Narrative) (Details) (USD $)	6 Months Ended					3 Months Ended		6 Months Ended
	Dec. 31, 2012	Jun. 30, 2012	Dec. 31, 2011	Sep. 06, 2011	Jun. 30, 2011	Dec. 31, 2012 Prostiva [Member]	Dec. 31, 2011 Prostiva [Member]	Dec. 31, 2012 Prostiva [Member]	Dec. 31, 2011 Prostiva [Member]
Business Acquisition [Line Items]
Term of Exclusive Worldwide License				10 years
Purchase price				$ 10,000,000
Market share percentage of BPH in office treatment				60.00%
Fair value of consideration to be paid to acquire Prostiva	7,000,000
Total initial licensing fee				1,000,000
Licensing fee paid				500,000
Fair value of payable	6,500,000
Licensing fees payable	500,000
Non-contingent consideration future cash payments				3,800,000
Contingent consideration, at fair value	2,109,000	2,862,000		2,700,000
Gain recognized related to fair value change of contingent consideration	791,000
Additional non-contingent consideration owed	422,000
Goodwill	3,036,000
Value of goodwill for tax purpose				1,700,000
Cumulative transaction expense	391,000		356,000
Transaction expense		288,000			103,000
License costs to maintain patents	65,000
Monthly transition service fee	30,000
Revenues						$ 1,500,000	$ 1,600,000	$ 2,900,000	$ 2,100,000